½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1547470

¼¼°èÀÇ ¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Women Health Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 128 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 882¾ï 8,000¸¸ ´Þ·¯¿¡¼­ 2032³â ¾à 1,506¾ï 8,000¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2024-2032³â ¿¬Æò±Õ 6.12%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀӽŠ°ü·Ã ÇÕº´Áõ, °¨¿°, ÀڱðæºÎ¾Ï, ³­¼Ò¾Ï, ÀÚ±ÃüºÎ¾Ï µîÀÇ Áø´Ü¿¡ »ç¿ëµÇ´Â Ä¡·áÁ¦, ¿ä¹ý, ¾àÇ°Àº ¿©¼º °Ç°­ Ä¡·áÁ¦·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ÃÖ±Ù ¿©¼º ºÒÀÓÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ãâ»êÀÌ ´Ê¾îÁö´Â »ç¶÷µéÀ» À§ÇÑ ºÒÀÓ Ä¡·áÁ¦ ¼­ºñ½º Á¦°øÀÌ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿©¼º ¼º±â´É Àå¾Ö Ä¡·áÁ¦¿¡ ´ëÇÑ ¹ÌÃæÁ· ¼ö¿ä°¡ ¿©¼º °Ç°­ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¿©¼º °Ç°­°ú ±× Ä¡·áÁ¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ½À´Ï´Ù. °¨¿°¼º Áúȯ, ¾Ï, ÀӽŰú °°Àº ¹®Á¦ Ä¡·áÁ¦¿Í °ü·ÃµÈ ÀǾàÇ°¿¡ ´ëÇÑ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½ÃÅ°±â À§ÇÑ ³ôÀº ÅõÀÚµµ ¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â ÁÖ¿ä ¿øµ¿·Â Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ¿©¼º °Ç°­ °ü·Ã ¸¸¼ºÁúȯ ¿¹¹æ¿¡ ´ëÇÑ ÀνÄÀÌ È®»êµÇ°í ÀÖ´Â °Íµµ ¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ°í ÀÖ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿©¼º¿¡°Ô ´õ ³ªÀº °Ç°­À» Á¦°øÇϱâ À§ÇÑ ¿¬±¸ °³¹ß À̴ϼÅƼºêÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ, ³ª»Û ¿µ¾ç ¼·Ãë¿Í »ýÈ°½À°ü º¯È­µµ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ ¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀå ¼ºÀå¿¡ È°·ÂÀ» ºÒ¾î³ÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª Ä¡·áÁ¦¿¡ µû¸¥ ³ôÀº Ä¡·á ºñ¿ë°ú Ä¡·áÁ¦ÀÇ »ç¿ë¿¡ µû¸¥ ºÎÀÛ¿ëÀº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â ¿äÀÎÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â »ê¾÷ ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆľÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀ̵˴ϴÙ. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¿©¼º °Ç°­ Ä¡·áÁ¦ ¼¼°è ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿©¼º °Ç°­ Ä¡·áÁ¦ »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ Á¢±Ù ¹æ½ÄÀ» ¼³¸íÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ª ¼öÁØÀÇ ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·« ´ã´çÀÚ°¡ °¢ Á¦Ç° ¹× ¼­ºñ½ºÀÇ Å¸°ÙÃþÀ» ½Äº°ÇÏ°í ÇâÈÄ ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀåÀÇ ÇöÀç¿Í ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ÀÀ¿ë ºÐ¾ß¿¡ ´ëÇÑ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ¿ä±¸»çÇ×ÀÌ ÀÖ´Â °æ¿ì, ÀúÈñ¿¡°Ô ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù. ´ç»çÀÇ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ¿©¼º °Ç°­ Ä¡·áÁ¦ - »ê¾÷ ºÐ¼®

  • ¼Ò°³ : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀÚÀç ºÐ¼®
    • ¿øÀÚÀç ¸®½ºÆ®
    • ¿øÀÚÀç Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀÚÀç °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆà ä³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆà ä³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¿©¼º °Ç°­ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ºÐ¼® : Ä¡·áÁ¦ À¯Çüº°

  • Ä¡·áÁ¦ À¯Çüº° °³¿ä
  • Ä¡·áÁ¦ À¯Çüº° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • È£¸£¸ó Ä¡·áÁ¦(¿¡½ºÆ®·Î°Õ ¿ä¹ý, Ȳüȣ¸£¸ó ¿ä¹ý, º´¿ë¿ä¹ý, °©»ó¼± º¸Ãæ ¿ä¹ý, ºÎ°©»ó¼±È£¸£¸ó ¿ä¹ý, ±âŸ)
  • ºñÈ£¸£¸ó Ä¡·áÁ¦(Ç¥Àû Ä¡·áÁ¦, Ç×»ýÁ¦, ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®, ±âŸ)

Á¦6Àå ¿©¼º °Ç°­ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ºÐ¼® : ÀûÀÀ Áúȯº°

  • ÀûÀÀ Áúȯº° °³¿ä
  • ÀûÀÀ Áúȯº° °ú°Å¡¤¿¹Ãø µ¥ÀÌÅÍ ºÐ¼®
  • ¾Ï(À¯¹æ¾Ï, ÀڱðæºÎ¾Ï, ³­¼Ò¾Ï)
  • °©»ó¼±±â´ÉÀúÇÏÁõ
  • Æó°æÈÄ ÁõÈıº
  • °ñ´Ù°øÁõ
  • ÇÇÀÓ
  • ÀڱñÙÁ¾
  • ¿ä·Î°¨¿°
  • ±âŸ

Á¦7Àå ¿©¼º °Ç°­ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼Ò°³
  • ºÏ¹Ì ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîƼ³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ¸®½ºÆ®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ¿©¼º °Ç°­ Ä¡·áÁ¦ ±â¾÷ °æÀï »óȲ

  • ¿©¼º °Ç°­ Ä¡·áÁ¦ ½ÃÀå °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤°è¾à
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦9Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • Eli Lilly And Company
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Amgen Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Allergan Plc
  • GlaxoSmithKline Plc
  • Lupin Pharmaceuticals Inc
ksm 24.09.25

The global demand for Women Health Therapeutics Market is presumed to reach the market size of nearly USD 150.68 Billion by 2032 from USD 88.28 Billion in 2023 with a CAGR of 6.12% under the study period 2024-2032.

A treatment, therapy, or drug that is used for the diagnosis of issues like pregnancy-related complications, infection, cervical cancer, ovarian cancer, and uterine cancer, etc is known as women's health therapeutics. Nowadays, infertility cases in women are rising, so the focus on providing fertility services to those with delayed childbirth is increasing. And, the unmet needs of the treatment of female sexual dysfunction are leading to the demand for women's health therapeutics.

MARKET DYNAMICS

Rising awareness about women's health and its treatment is the key market driver for the growth of the women's health therapeutics market. High investments made to meet the unmet demands of drugs related to the treatment of issues like infections, cancer, pregnancy, etc is also one of the major driving force responsible for the market growth of women health therapeutics. The growing prevalence of prevention of chronic diseases related to women's health is also assumed to steer the market growth of women's health therapeutics. An increase in research and development initiatives for providing better health to women will further propel the market growth. Furthermore, bad nutritional intake and change in lifestyle are also expected to increase the demand for therapeutics and exhilarate the market growth of women's health therapeutics. However, the high treatment cost associated with the treatment and side effects associated with the usage of the therapeutics may restraint the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Women Health Therapeutics. The growth and trends of Women Health Therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Women Health Therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

  • Hormonal Treatment (Estrogen Therapy, Progestin Therapy, Combination Therapy, Thyroid Replacement Therapy, Parathyroid Hormone Therapy, Others)
  • Non-hormonal Treatment (Targeted Therapy Drugs, Antibiotics, Bisphosphonates, Others)

By Disease Indication

  • Cancer (Breast Cancer, Cervical Cancer, Ovarian Cancer)
  • Hypothyroidism
  • Post-menopausal Syndrome
  • Osteoporosis
  • Contraception
  • Uterine Fibroid
  • Urinary Tract Infection
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Women Health Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Women Health Therapeutics market include Eli Lilly And Company, Novartis AG, Pfizer Inc., Merck & Co. Inc., Novo Nordisk A/S, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi, Allergan Plc, GlaxoSmithKline Plc, Lupin Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. WOMEN HEALTH THERAPEUTICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Disease Indication
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data Analysis By Treatment Type
  • 5.3. Hormonal Treatment (Estrogen Therapy, Progestin Therapy, Combination Therapy, Thyroid Replacement Therapy, Parathyroid Hormone Therapy, Others) Historic and Forecast Sales By Regions
  • 5.4. Non-hormonal Treatment (Targeted Therapy Drugs, Antibiotics, Bisphosphonates, Others) Historic and Forecast Sales By Regions

6. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET ANALYSIS BY DISEASE INDICATION

  • 6.1. Overview By Disease Indication
  • 6.2. Historical and Forecast Data Analysis By Disease Indication
  • 6.3. Cancer (Breast Cancer, Cervical Cancer, Ovarian Cancer) Historic and Forecast Sales By Regions
  • 6.4. Hypothyroidism Historic and Forecast Sales By Regions
  • 6.5. Post-menopausal Syndrome Historic and Forecast Sales By Regions
  • 6.6. Osteoporosis Historic and Forecast Sales By Regions
  • 6.7. Contraception Historic and Forecast Sales By Regions
  • 6.8. Uterine Fibroid Historic and Forecast Sales By Regions
  • 6.9. Urinary Tract Infection Historic and Forecast Sales By Regions
  • 6.10. Others Historic and Forecast Sales By Regions

7. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE WOMEN HEALTH THERAPEUTICS COMPANIES

  • 8.1. Women Health Therapeutics Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF WOMEN HEALTH THERAPEUTICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Eli Lilly And Company
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Novartis AG
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Pfizer Inc.
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. Merck & Co. Inc.
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Novo Nordisk A/S
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. Amgen Inc.
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. AstraZeneca
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. F. Hoffmann-La Roche Ltd.
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. Sanofi
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments
  • 9.12. Allergan Plc
    • 9.12.1 Company Overview
    • 9.12.2 Company Revenue
    • 9.12.3 Products
    • 9.12.4 Recent Developments
  • 9.13. GlaxoSmithKline Plc
    • 9.13.1 Company Overview
    • 9.13.2 Company Revenue
    • 9.13.3 Products
    • 9.13.4 Recent Developments
  • 9.14. Lupin Pharmaceuticals Inc
    • 9.14.1 Company Overview
    • 9.14.2 Company Revenue
    • 9.14.3 Products
    • 9.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦